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Background: There is a concern that topical tacrolimus and pimecrolimus, indicated for 
second-line treatment of atopic dermatitis, may increase the risk of lymphoma and skin cancer, 
particularly in children.
Objective: The aim of this study was to compare incidence rates (IRs) of lymphoma and skin 
cancer between new users of topical tacrolimus or pimecrolimus and users of moderate- to 
high-potency topical corticosteroids (TCSs) and untreated subjects.
Methods: This is a multicenter cohort study with frequency matching by strata of propensity 
scores in population databases in the Netherlands, Denmark, Sweden, and the UK. IR ratios 
(IRRs) were estimated using Mantel–Haenszel methods for stratified analysis.
Results: We included 19,948 children and 66,127 adults initiating tacrolimus, 23,840 children 
and 37,417 adults initiating pimecrolimus, 584,121 users of TCSs, and 257,074 untreated sub-
jects. IRs of lymphoma per 100,000 person-years were 10.4 events in children and 41.0 events 
in adults using tacrolimus and 3.0 events in children and 27.0 events in adults using pimecro-
limus. The IRR (95% confidence interval [CI]) for lymphoma, tacrolimus versus TCSs, was 
3.74 (1.00–14.06) in children and 1.27 (0.94–1.71) in adults. By lymphoma type, the highest 
IRR was 3.17 (0.58–17.23) for Hodgkin lymphoma in children and 1.76 (95% CI, 0.81–3.79) 
for cutaneous T-cell lymphoma (CTCL) in adults. For pimecrolimus versus TCSs, the highest 
IRR was 1.31 (95% CI, 0.33–5.14) for CTCL in adults. Compared with untreated subjects, 
adults using TCSs had a higher incidence of CTCL (IRR, 10.66; 95% CI, 2.60–43.75). Smaller 
associations were found between tacrolimus and pimecrolimus use and the risk of malignant 
melanoma or nonmelanoma skin cancer.
Conclusion: Use of topical tacrolimus and pimecrolimus was associated with an increased 
risk of lymphoma. The low IRs imply that even if the increased risk is causal, it represents a 
small excess risk for individual patients. Residual confounding by severity of atopic dermatitis, 
increased monitoring of severe patients, and reverse causation could have affected the results.
Keywords: topical calcineurin inhibitors, cutaneous T-cell lymphoma, malignant melanoma 
skin cancer, database study
Introduction
Topical tacrolimus and pimecrolimus are topical calcineurin inhibitors indicated 
for second-line treatment of atopic dermatitis in children aged 2 years and older. 
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 Tacrolimus is indicated for moderate-to-severe atopic der-
matitis, and pimecrolimus is indicated for mild-to-moderate 
atopic dermatitis.
The long-term safety of these agents is not well estab-
lished. Safety data from animal studies, systemic use in 
patients with organ transplants, and case reports have raised 
concerns about a potential increase in the risk of lymphoma 
and skin cancer.1–4 Data from observational studies are scarce 
and inconclusive, particularly in children. Some studies 
reported an increased risk for lymphoma, particularly for 
cutaneous T-cell lymphoma (CTCL), among users of these 
medications, but other studies did not find any association.5–8 
Some of these studies had a small study size and short follow-
up.5,6 The causal effect of tacrolimus and pimecrolimus is 
difficult to elucidate as atopic dermatitis itself and severity 
of atopic dermatitis have been associated with an increased 
risk of lymphoma.9,10
To further evaluate the safety of topical tacrolimus and 
pimecrolimus, we conducted a postauthorization study 
of children and adults in four European population-based 
databases. Using data from launch until the end of 2011, we 
compared the incidence rates (IRs) of nonmelanoma skin can-
cer, malignant melanoma, and lymphoma between patients 
initiating treatment with these agents and users of moderate- 
to high-potency topical corticosteroids (TCSs). The study has 
been extended 4 years to assess long-term effects.
Methods
Source population
We conducted a multicenter database cohort study in popu-
lations from the PHARMO Database Network in the Neth-
erlands (PHARMO), the Danish and the Swedish national 
health registers, and the Clinical Practice Research Datalink 
(CPRD) in the UK.
The study population comprised children (aged 
<18 years) and adults (aged ≥18 years) initiating treatment 
with topical tacrolimus or pimecrolimus or treated with TCSs, 
from 2002 to 2011, who had at least 12 months of continuous 
enrollment in the study databases. Initiation of tacrolimus 
and pimecrolimus was defined as not having any prescription 
for either medication at any time before the date of cohort 
entry. Study TCSs were those classified as moderately potent, 
potent, or very potent in the Anatomical Therapeutic Chemi-
cal (ATC) classification.11 Users of TCSs were required to 
have a recorded diagnosis of atopic dermatitis or at least one 
additional prescription for TCSs in the 12 months before 
cohort entry. Because the study focused on incident events, 
we excluded all users with a history of any study outcome 
before cohort entry from the study population.
Study cohorts
Users of TCSs were frequency matched by twentiles (20 
quantiles) of propensity scores to initiators of tacrolimus or 
pimecrolimus (Figure 1). Propensity scores were estimated 
in each database as the predicted probability of receiving 
treatment with tacrolimus or pimecrolimus instead of TCSs 
given a set of baseline covariates. Variables included in 
the estimation of propensity scores were those showing an 
association (odds ratio >1.25 or <0.80) in logistic regression 
models fitted for each study outcome as the independent 
variable. To account for patients with nonoverlapping pro-
pensity scores, patients below the 2.5th percentile and above 
the 97.5th percentile of the distribution of propensity scores 
were excluded.12 Within each stratum, frequency matching 
was conducted by randomly selecting users of TCSs from 
the eligible pool until reaching the matching ratio (4:1, 
TCSs to study drug). Variables evaluated in the estimation 
of propensity scores were age, sex, calendar year of cohort 
entry, health practice or region, medical history, and use of 
medications and health care resources (Table 1). Medical 
diagnoses were identified by Read codes and International 
Statistical Classification of Diseases and Related Health 
Problems, 10th revision (ICD-10) codes in CPRD, ICD-9 
codes in PHARMO, and ICD-10 codes in Denmark and 
 Sweden. Medications were identified by ATC codes. In 
CPRD, the National Health Service Dictionary of Medicines 
and Devices codes were mapped to ATC codes using Safe-
Script (www.safescript.com).
From the general population, we identified a secondary 
cohort of subjects untreated with tacrolimus, pimecrolimus, 
or TCSs. Untreated subjects were matched in a 1:1 ratio to 
the cohort of users of TCSs identified as the comparative 
cohort for tacrolimus. Matching was done on year of birth, 
sex, health practice/region (except in Denmark), and calendar 
year of cohort entry. Patients from each study cohort were 
followed from the date of cohort entry to the earliest occur-
rence of first study outcome, death, disenrollment from the 
study database, or December 31, 2011.
Exposure definition
Patterns of use of tacrolimus and pimecrolimus in the study 
populations have been described elsewhere.13 We assumed 
that the time at risk associated with the use of tacrolimus 
and pimecrolimus started 6 months after cohort entry and 
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Figure 1 Study cohorts.
Note: “Corticosteroids” refer to moderate- to high-potency topical corticosteroids.
Corticosteroids
cohort for
tacrolimus
Users of
corticosteroids
Study population
Inclusion criteria
≥12 months continuous
enrollment
Individual matching
by age, sex, region,
and calendar year
Propensity scores
Frequency matching
Propensity scores
Frequency matching
Source population
Tacrolimus
cohort
Corticosteroids
cohort for
pimecrolimus
Pimecrolimus
cohort
Untreated
cohort
Covariate Categorization Included in score
Demographic information
Age at cohort entry (years) •	 Children: 0–1, 2–4, 5–9, 10–14, 15–17
•	 Adults: 18–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, 85+
Yes
Sex •	 Female, male Yes
Calendar year of cohort entry •	 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011 No
Primary care health practice/
geographic region or outpatient 
pharmacy geographic region code
No
Atopic dermatitis
Diagnosis •	 Outpatient or hospital discharge diagnosis of atopic dermatitis at any time before the 
start date
Yes
Severity Yes/no; according to use of health care resources in the year before cohort entry:
•	 At least one visit to a dermatologist for patients younger than 3 years (information 
not available in PHARMO)
•	 At least four physician or pediatrician visits for atopic dermatitis in patients aged 
3 years or older (information not available in PHARMO)
•	 At least one hospitalization with a primary discharge diagnosis for atopic dermatitis
Yes
Other medical history Yes/no categories ascertained by outpatient (GP, specialist, and hospital outpatient) 
and/or hospital discharge diagnosis recorded at any time before cohort entry 
Disease interacting with the 
immune system
•	 Psoriasis
•	 Epstein–Barr virus infection
•	 Rheumatoid arthritis
•	 Systemic lupus erythematosus
•	 Sjögren’s syndrome
•	 Celiac sprue
•	 Asthma
•	 Allergic rhinitis
•	 Diseases of the immune system
Yes
Skin disease (excluding atopic 
dermatitis, eczema, and psoriasis) 
•	 Inflammatory skin diseases
•	 Sunburn
•	 Other skin diseases
Yes
Table 1 Variables evaluated in the estimation of propensity scores
(Continued)
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Covariate Categorization Included in score
Chronic disease •	 Malignancy excluding skin cancer and lymphoma
•	 Renal failure
•	 Chronic liver disease and hepatic failure
•	 Ischemic heart disease
•	 Hypertensive disease
•	 Heart failure
•	 Other cardiovascular diseases
•	 Cerebrovascular diseases
•	 Diabetes mellitus
•	 COPD, emphysema, respiratory insufficiency
•	 Musculoskeletal system and connective tissue disease (excluding rheumatoid arthritis, 
systemic lupus erythematosus, and Sjögren’s syndrome)
•	 Organ transplantation
•	 HIV infection or AIDSa
Yes
Use of medications At least one prescription recorded within 12 months before cohort entry (yes/no, 
unless other parameters are specified)
Use of immunosuppressant and 
cytostatic drugs
•	 Systemic corticosteroids
•	 Systemic tacrolimus
•	 Azathioprine
•	 Methotrexate
•	 Cyclosporin
•	 Other immunosuppressants
•	 Systemic antivirals
•	 Antineoplastic agents excluding methotrexate
Yes
Antipsoriatics for topical use •	 Tars
•	 Anthracene derivatives: dithranol and dithranol combinations
•	 Psoralens for topical use: trioxsalen, methoxsalen
•	 Other antipsoriatics for topical use: fumaric acid, calcipotriol, calcitriol, tacalcitol, 
tazarotene, calcipotriol combinations
No
Other dermatological preparations 
excluding topical corticosteroids 
•	 Topical salicylic acid preparations
•	 Other dermatological agents
No
Other drugs •	 Cardiovascular system drugs (excluding lipid-modifying agents)
•	 Anti-inflammatory and antirheumatic agents, nonsteroidal
•	 Other antirheumatic agents
•	 Hormone-replacement therapy
•	 Lipid-modifying agents
•	 Insulins
•	 Oral antidiabetics
•	 Antiepileptics
•	 Drugs for asthma and obstructive airways disease
No
Utilization of health care 
resources
•	 In the 12 months before cohort entry
Outpatient (information not 
available in PHARMO)
Categories for all types of visits:
0, 1, 2–3, 4+
•	 Number of visits to general practitioner
•	 Number of visits to dermatologist
•	 Number of visits to pediatrician
•	 Number of emergency department visits
•	 Number of outpatient hospital visits
Yes
Inpatient •	 Number of hospitalizations (excluding emergency department visits and hospital 
outpatient visits): 0, 1, 2–3, 4+
Yes
Prescriptions •	 Number of prescriptions: 0, 1, 2–4, 5–9, 10+ Yes
Notes: PHARMO, PHARMO Database Network (the Netherlands). aInformation on HIV/AIDS was not available in the Swedish database.
Abbreviations: COPD, chronic obstructive pulmonary disease; GP, general practitioner; HIV, human immunodeficiency virus.
Table 1 (Continued)
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 continued until the end of follow-up (induction period). 
Person-time of follow-up was classified as ever use of tacro-
limus or pimecrolimus, ignoring any potential switching 
between the two agents. In addition, we defined single use of 
tacrolimus and single use of pimecrolimus as the person-time 
starting 6 months after the date of cohort entry to the earliest 
of 6 months after the date of switching to either tacrolimus 
or pimecrolimus or end of follow-up.
We calculated the cumulative dose of active substance of 
tacrolimus and pimecrolimus that patients received during 
follow-up. Cumulative dose was defined as low, medium, 
or high according to break points established prior to the 
analysis based on the distribution of cumulative dose in each 
database. Cutoff values for tacrolimus were ≤0.05 g for low 
dose, >0.05–0.10 g for medium dose, and >0.10 g for high 
dose. Cutoff values for pimecrolimus were ≤0.5 g for low 
dose, >0.5–1.0 g for medium dose, and >1.0 g for high dose. 
For each level of cumulative dose, the time at risk started 
6 months after reaching the corresponding cutoff value.
Study outcomes
The study outcomes were malignant melanoma, nonmela-
noma skin cancer, any lymphoma, non-Hodgkin lymphoma 
(excluding CTCL), Hodgkin lymphoma, and CTCL. In situ 
tumors were included in the definition of malignant mela-
noma and nonmelanoma skin cancer.
Outcomes were identified in 1) cancer registries in Denmark, 
Sweden, and CPRD (linked practices), 2) the Dutch National 
Pathology Registry (PALGA) in PHARMO, and 3) primary care 
records in CPRD for practices not linked to the cancer registry. 
Outcomes were identified using International Classification 
of Diseases for Oncology, third edition (ICD-O-3) codes in 
 Denmark and Sweden, PALGA codes mapped to ICD-O-3 codes 
in PHARMO, and Read and ICD-10 codes in CPRD. Outcomes 
identified in the cancer registries were considered confirmed.14–17 
In PHARMO, an independent pathologist reviewed the pathol-
ogy excerpts of all pediatric outcomes, all CTCLs, and a random 
sample of adult outcomes. Overall, 98.0% of outcomes were 
confirmed. In CPRD, we performed a clinical review of patient 
profiles and free-text fields for all pediatric outcomes, all CTCLs, 
all outcomes identified in the primary care record, and all out-
comes with inconsistent information between the primary care 
record and the cancer registry. A total of 864 outcomes were 
reviewed, and 762 (88.2%) were confirmed.
Analysis
In each database, person-years of follow-up and number of 
outcomes were aggregated across deciles of propensity scores 
(after aggregating neighboring pairs of strata from the initial 
twentiles used to match the study cohorts), age categories, 
and sex. We applied Mantel–Haenszel methods for stratified 
analyses to estimate IRs, adjusted IR ratios (IRRs) and IR dif-
ferences (IRD), and 95% confidence intervals (CIs) for each 
study outcome and type of exposure, maintaining database 
as a stratification variable. Because recorded information on 
the severity of atopic dermatitis was scarce in all databases, 
we further adjusted IRRs by the type of prescriber of the 
first prescription (dermatologist and nondermatologist), as a 
marker of atopic dermatitis severity, in those databases where 
this information was available (PHARMO and Sweden). To 
account for the effect of type of prescriber in Denmark and 
CPRD, we used information from PHARMO and Sweden to 
correct adjusted IRRs using quantitative probabilistic bias 
analysis for unmeasured confounders (“Methods” section in 
the Supplementary materials).18 These IRRs are presented as 
corrected IRRs (IRRc). To evaluate latency of the effect of 
exposure and reverse causation, we estimated IRRs by time 
since first exposure and for additional lag-times.
We obtained ethical and scientific reviews from the 
RTI International Institutional Review Board, the Regional 
Ethical Review Board of Stockholm, the CPRD Independent 
Scientific Advisory Committee, and the UK National Cancer 
Intelligence Network. Ethical approval was not required in 
PHARMO and Denmark. In PHARMO, the study fulfilled 
the requirements of the PHARMO Compliance Commis-
sion, and permission for the use of data from PALGA was 
obtained. In Denmark, the study was approved by the Danish 
Data Protection Agency via Statistics Denmark. The study 
was registered in the European Union Electronic Register 
of Post-Authorisation Studies (EU PAS Register) study 
number 4357.19
Results
The study included 19,948 children and 66,127 adults initiat-
ing treatment with tacrolimus and 23,840 children and 37,417 
adults initiating treatment with pimecrolimus (Table 2). 
Among users of TCSs, 79,700 children and 264,482 adults 
were matched to new users of tacrolimus and 90,268 children 
and 149,671 adults were matched to new users of pimecro-
limus. The untreated cohort comprised 79,040 children 
and 257,074 adults. In general, the matching on propensity 
scores achieved a good balance between the study cohorts 
(Tables S1 and S2).
The median follow-up ranged from 2.2 years ( Sweden) to 
4.2 years (CPRD) in children and from 2.2 years ( Sweden) 
to 3.6 years (Denmark and CPRD) in adults treated with 
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 tacrolimus and from 3.2 years (Sweden) to 6.5 years 
( Denmark) in children and from 2.8 years (Sweden) to 
5.6 years (Denmark) in adults treated with pimecrolimus.
Among children treated with tacrolimus, there were no 
events of malignant melanoma or nonmelanoma skin cancer 
and five events of any lymphoma (Table 3). The IR of any 
lymphoma was higher in children treated with tacrolimus 
than in children treated with TCSs (IRRc, 3.74; 95% CI, 
1.00–14.1) (Table 3). Among adults, there was a negative 
association between the use of tacrolimus and malignant 
melanoma and no association with nonmelanoma skin cancer. 
For any lymphoma, the IRRc comparing adults treated with 
Table 2 Distribution of users by study cohort and population
Study database Topical 
tacrolimus, 
n (%)
Topical 
corticosteroidsa, 
n (%)
Topical 
pimecrolimus, 
n (%)
Topical 
corticosteroidsb, 
n (%)
Topical 
corticosteroidsc, 
n (%)
Untreated 
cohortc, n (%)
Children, 0–<18 years 
PHARMO 3,030 (15.2) 12,033 (15.1) 2,097 (8.8) 8,388 (9.3) 11,948 (15.1) 11,948 (15.1)
Denmark 7,844 (39.3) 31,376 (39.4) 18,872 (79.2) 70,397 (78.0) 31,309 (39.5) 31,103 (39.4)
Sweden 7,128 (35.7) 28,508 (35.8) 1,049 (4.4) 4,195 (4.6) 28,205 (35.6) 28,205 (35.7)
CPRD 1,946 (9.8) 7,783 (9.8) 1,822 (7.6) 7,288 (8.1) 7,783 (9.8) 7,784 (9.8)
Total 19,948 (100) 79,700 (100) 23,840 (100) 90,268 (100) 79,245 (100) 79,040 (100)
Adults, ≥18 years 
PHARMO 13,606 (20.6) 54,424 (20.6) 5,713 (15.3) 22,852 (15.3) 54,247 (21.1) 54,247 (21.1)
Denmark 17,987 (27.2) 71,948 (27.2) 25,387 (67.8) 101,548 (67.8) 72,012 (28.0) 71,739 (27.9)
Sweden 28,765 (43.5) 115,036 (43.5) 3,334 (8.9) 13,335 (8.9) 108,027 (42.0) 108,027 (42.0)
CPRD 5,769 (8.7) 23,074 (8.7) 2,983 (8.0) 11,936 (8.0) 23,062 (9.0) 23,061 (9.0)
Total 66,127 (100) 264,482 (100) 37,417 (100) 149,671 (100) 257,348 (100) 257,074 (100)
Notes: PHARMO, PHARMO Database Network (the Netherlands). aCohort of users of moderate- to high-potency topical corticosteroids matched to the tacrolimus 
cohort. bCohort of users of moderate- to high-potency topical corticosteroids matched to the pimecrolimus cohort. cUntreated cohort matched to users of moderate- to 
high-potency topical corticosteroids on year of birth, sex, primary care general practice/region, and calendar year of cohort entry.
Abbreviation: CPRD, Clinical Practice Research Datalink.
Table 3 IR per 100,000 person-years, rate ratio, and rate difference of each study outcome for single use of topical tacrolimus and 
moderate- to high-potency topical corticosteroids
Study outcome Topical tacrolimus Topical 
corticosteroids
Adjusteda IRR 
(95% CI)
Correctedb IRR 
(95% CI)
Adjusteda IRD  
(95% CI)
Number of 
events
IR Number of 
events
IR
Children, 0–<18 years (47,872 person-
years)
(191,074 
person-years)
MM 0 0.0 2 1.0 NE 0.00 (0.00–0.00) –1.0 (–3.9, 1.9)c
NMSC 0 0.0 1 0.5 NE 0.00 (0.00–0.00) –0.5 (–2.6, 1.5)c
Lymphoma 5 10.4 4 2.1 5.26 (1.14–24.29) 3.74 (1.00–14.06) 7.9 (–1.1, 16.9)
NHL 2 4.2 1 0.5 7.53 (0.12–486.93) 1.47 (0.26–8.20) 2.4 (–1.5, 6.4)
HL 2 4.2 3 1.6 3.11 (0.55–17.67) 3.17 (0.58–17.23) 3.1 (–3.5, 9.8)
CTCL 1 2.1 0 0.0 NE 0.00 (0.00–0.00) 2.3 (–2.3, 7.0)c
Adults, ≥18 years (190,412  
person-years)
(777,075 
person-years)
MM 61 32.0 270 34.7 0.90 (0.67–1.21) 0.90 (0.66–1.22) –3.5 (–13.3, 6.2)
NMSC 622 326.7 2,224 286.2 1.12 (1.01–1.23) 1.08 (0.98–1.19) 34.2 (3.5, 64.9)
Lymphoma 78 41.0 199 25.6 1.47 (1.10–1.95) 1.27 (0.94–1.71) 12.7 (2.4, 22.9)
NHL 50 26.3 141 18.1 1.34 (0.95–1.91) 1.21 (0.84–1.75) 6.6 (–1.8, 14.9)
HL 10 5.3 34 4.4 1.08 (0.50–2.32) 1.16 (0.51–2.63) 0.4 (–3.4, 4.1)
CTCL 18 9.5 24 3.1 2.71 (1.35–5.44) 1.76 (0.81–3.79) 5.8 (1.2, 10.4)
Notes: PHARMO, PHARMO Database Network (the Netherlands). Topical corticosteroids refer to moderate- to high-potency topical corticosteroids. aAdjusted by study 
database; deciles of propensity scores; sex; and, in PHARMO and Sweden, type of prescriber of first prescription (dermatologist and nondermatologist). bCorrected for the 
effect of type of prescriber of first prescription in Denmark and CPRD after applying quantitative bias analysis for unmeasured confounders. cCrude IRD.
Abbreviations: CI, confidence interval; CPRD, Clinical Practice Research Datalink; CTCL, cutaneous T-cell lymphoma; HL, Hodgkin lymphoma; IR, incidence rate; IRD, IR 
difference; IRR, IR ratio; MM, malignant melanoma including in situ tumors; NE, not estimable; NHL, non-Hodgkin lymphoma; NMSC, nonmelanoma skin cancer including in 
situ tumors.
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tacrolimus and TCSs was 1.27 (95% CI, 0.94–1.71). By type 
of lymphoma, the highest IRR was for CTCL (IRRc, 1.76; 
95% CI, 0.81–3.79).
Among children treated with pimecrolimus, there were no 
events of malignant melanoma, one event of nonmelanoma 
skin cancer, and three events of lymphoma (Table 4). The IR 
(95% CI) per 100,000 person-years of nonmelanoma skin 
cancer was 0.9 (0–5.3) in children treated with pimecrolimus 
and 0.3 (0–1.6) in children treated with TCSs.
No marked increased rates of any lymphoma were found 
in children treated with pimecrolimus. In adults treated with 
pimecrolimus, the IR (95% CI) per 100,000 person-years was 
41.1 (32.1–51.9) for malignant melanoma, 360.8 (333.1–
390.3) for nonmelanoma skin cancer, and 1.7 (0.4–5.1) for 
CTCL compared with the IR (95% CI) per 100,000 person-
years for adults treated with TCSs: 33.9 (29.7–38.6), 269.1 
(256.9–281.7), and 1.6 (0.8–2.9), respectively.
Compared to untreated subjects, in general, users of TCSs 
had increased IRs of skin cancer and lymphoma (Table 5). 
The highest IRRc was 10.7 (95% CI, 2.6–44) for CTCL in 
adults. The actual IR for cohorts of TCSs matched to pimecro-
limus or tacrolimus differed (refer “Results” section in the 
Supplementary materials).
IRRs for any lymphoma and CTCL increased with 
increasing cumulative dose of tacrolimus and pimecrolimus 
(Table 6). Analysis by time since first exposure in children 
showed no events in the first 6 months after the start of tacro-
limus or pimecrolimus (Table S3). In adults, IRRs of skin 
cancer and CTCL were higher in the first 6 months after the 
start of tacrolimus or pimecrolimus than in the subsequent 
months (Table S4).
IRRs for any lymphoma in children treated with tacro-
limus or pimecrolimus were higher for lag times 0 and 
6 months than for lag times 12 and 24 months (Tables S5 
and S6). In adults, IRRs for CTCL increased with longer lag 
times in users of tacrolimus and decreased with longer lag 
times in users of pimecrolimus.
Discussion
In this European multicenter study, we found an approxi-
mately fourfold increase in the IR of lymphoma in children 
initiating treatment with tacrolimus and a less than twofold 
increase in the IR of CTCL in adults initiating treatment with 
tacrolimus or pimecrolimus compared with users of TCSs. 
We also found a >10-fold increase in the rate of CTCL in 
adults treated with TCSs compared with untreated subjects, 
Table 4 IR per 100,000 person-years, rate ratio, and rate difference of each study outcome for single use of topical pimecrolimus and 
moderate- to high-potency topical corticosteroids
Study outcome Topical pimecrolimus Topical 
corticosteroids
Adjusteda IRR 
(95% CI)
Correctedb IRR 
(95% CI)
Adjusteda IRD 
(95% CI)
Number of 
events
IR Number of 
events
IR
Children, 0–<18 years (98,689 
person-years)
(350,957 
person-years)
MM 0 0.0 1 0.3 NE 0.00 (0.00–0.00) –0.3 (–1.3, 0.8)c
NMSC 1 1.0 1 0.3 3.84 (0.25–58.81) 1.24 (0.21–7.41) 0.8 (–1.4, 2.9)
Any lymphoma 3 3.0 6 1.7 1.81 (0.41–8.02) 1.07 (0.25–4.60) 1.3 (–2.2, 4.8) 
NHL 1 1.0 2 0.6 1.93 (0.17–22.02) 1.28 (0.22–7.53) 0.5 (–1.7, 2.7)
HL 2 2.0 4 1.1 1.75 (0.27–11.44) 1.22 (0.27–5.54) 0.8 (-2.0, 3.6)
CTCL 0 0.0 0 0.0 NE 0.00 (0.00–0.00) NE
Adults, ≥18 years (159,530 
person-years)
(680,797 
person-years)
MM 68 42.6 231 33.9 1.24 (0.94–1.64) 1.16 (0.87–1.56) 8.2 (–2.9, 19.2)
NMSC 581 364.2 1,832 269.1 1.34 (1.22–1.47) 1.20 (1.07–1.35) 93.6 (60.9, 126.2)
Any lymphoma 43 27.0 147 21.6 1.22 (0.86–1.72) 1.03 (0.71–1.51) 4.7 (–4.1, 13.5)
NHL 31 19.4 103 15.1 1.25 (0.82–1.89) 1.10 (0.67–1.80) 3.7 (–3.6, 11.1)
HL 9 5.6 33 4.8 1.15 (0.56–2.37) 1.16 (0.55–2.47) 0.8 (–3.5, 5.0)
CTCL 3 1.9 11 1.6 1.11 (0.28–4.32) 1.31 (0.33–5.14) 0.2 (–2.1, 2.4)
Notes: PHARMO, PHARMO Database Network (the Netherlands). Topical corticosteroids refer to moderate- to high-potency topical corticosteroids. aAdjusted by study 
database; deciles of propensity scores; sex; and, in PHARMO and Sweden, type of prescriber of first prescription (dermatologist and nondermatologist). bCorrected for the 
effect of type of prescriber of first prescription in Denmark and CPRD after applying quantitative bias analysis for unmeasured confounders. cCrude IRD.
Abbreviations: CI, confidence interval; CPRD, Clinical Practice Research Datalink; CTCL, cutaneous T-cell lymphoma; HL, Hodgkin lymphoma; IR, incidence rate; IRD, IR 
difference; IRR, IR ratio; MM, malignant melanoma including in situ tumors; NE, not estimable; NHL, non-Hodgkin lymphoma; NMSC, non-melanoma skin cancer including 
in situ tumors.
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Table 5 IR per 100,000 person-years, rate ratio, and rate difference of each study outcome for single use of moderate- to high-potency 
topical corticosteroids and the untreated population
Study outcome Topical corticosteroidsa Untreated populationb Matched IRR  
(95% CI)
Matched IRD  
(95% CI)Number of events IR Number of events IR
Children, 0–<18 years (195,631  
person-years)
(189,798  
person-years)
 MM 2 1.0 1 0.5 1.93 (0.16–23.03) 0.5 (–1.2, 2.2)
 NMSC 1 0.5 1 0.5 0.94 (0.06–15.66) 0.0 (–1.5, 1.4)
 Any lymphoma 4 2.0 0 0.0 NE 2.1 (0.0, 4.1)c 
 NHL 1 0.5 0 0.0 NE 0.5 (–0.5, 1.6)c
 HL 3 1.5 0 0.0 NE 1.6 (–0.2, 3.3)c
 CTCL 0 0.0 0 0.0 NE NE
Adults, ≥18 years (789,435  
person-years)
(717,457  
person-years)
 MM 263 33.3 276 38.5 0.87 (0.74–1.03) –4.9 (–10.9, 1.2)
 NMSC 2,166 274.4 1,652 230.3 1.19 (1.11–1.27) 43.4 (27.4, 59.4)
 Any lymphoma 196 24.8 119 16.6 1.49 (1.19–1.87) 8.2 (3.6, 12.8)
 NHL 138 17.5 105 14.6 1.19 (0.93–1.53) 2.8 (–1.2, 6.9)
 HL 34 4.3 12 1.7 2.55 (1.32–4.90) 2.6 (0.9, 4.4)
 CTCL 24 3.0 2 0.3 10.66 (2.60–43.75) 2.8 (1.5, 4.1)
Notes: Topical corticosteroids refer to moderate- to high-potency topical corticosteroids. aCohort of users of moderate- to high-potency topical corticosteroids identified 
as the comparative cohort for topical tacrolimus. bUntreated cohort matched to users of moderate- to high-potency topical corticosteroids on year of birth, sex, primary 
care general practice/region (except in Denmark), and calendar year of cohort entry. cCrude IRD.
Abbreviations: CI, confidence interval; CTCL, cutaneous T-cell lymphoma; HL, Hodgkin lymphoma; IR, incidence rate; IRD, IR difference; IRR, IR ratio; MM, malignant 
melanoma including in situ tumors; NE, not estimable; NHL, non-Hodgkin lymphoma; NMSC, non-melanoma skin cancer including in situ tumors.
Table 6 IR per 100,000 person-years and rate ratio of lymphoma and CTCL by cumulative dose of active substance for single use of 
topical tacrolimus and topical pimecrolimus versus moderate- to high-potency topical corticosteroids in adults
Study outcome and exposure Person-years Number of events IR Adjusteda IRR (95% CI)
Topical tacrolimus
Any lymphoma
Topical corticosteroids 777,075 199 25.6 1.00
Topical tacrolimus (g)b
≤0.05 122,230 47 38.5 1.40 (1.00–1.97)
>0.05–0.10 40,436 12 29.7 1.06 (0.59–1.92)
>0.10 27,746 19 68.5 2.27 (1.39–3.69)
CTCL
Topical corticosteroids 777,075 24 3.1 1.00
Topical tacrolimus (g)b
≤0.05 122,230 8 6.5 1.81 (0.71–4.63)
>0.05–0.10 40,436 4 9.9 3.39 (1.22–9.47)
>0.10 27,746 6 21.6 6.19 (2.28–16.79)
Topical pimecrolimus
Any lymphoma
Topical corticosteroids 680,797 147 21.6 1.00
Topical pimecrolimus (g)c
≤0.5 125,352 24 19.1 0.89 (0.57–1.37)
>0.5–1.0 20,248 10 49.4 2.25 (1.19–4.26)
>1.0 13,930 9 64.6 2.55 (1.27–5.12)
CTCL
Topical corticosteroids 680,797 11 1.6 1.00
Topical pimecrolimus (g)c
≤0.5 125,352 1 0.8 0.52 (0.07–3.93)
>0.5–1.0 20,248 1 4.9 3.21 (0.29–35.73)
>1.0 13,930 1 7.2 4.46 (0.54–36.58)
Notes: PHARMO, PHARMO Database Network (the Netherlands). Topical corticosteroids refer to moderate- to high-potency topical corticosteroids. aAdjusted by study 
database; deciles of propensity scores; sex; and, in PHARMO and Sweden, type of prescriber of first prescription (dermatologist and nondermatologist). bA cumulative dose 
of 0.10 g of active substance corresponds to 5.6 tubes of 60 g tacrolimus 0.03% ointment (1.7 tubes of 60 g tacrolimus 0.1% ointment). cA cumulative dose of 1 g of active 
substance corresponds to 1.7 tubes of 60 g pimecrolimus 1% ointment.
Abbreviations: CI, confidence interval; CTCL, cutaneous T-cell lymphoma; IR, incidence rate; IRR, IR ratio.
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implying that the contrast in rates between users of tacrolimus 
and an untreated population would be considerably high. 
We found smaller associations for malignant melanoma or 
nonmelanoma skin cancer. CIs around effect estimates tended 
to be wide, especially for children, indicating low precision.
This is the first observational study reporting results on 
the risk of lymphoma and skin cancer for children treated 
only with tacrolimus and the largest study, with the longest 
follow-up, conducted in adults. The study has been extended 
for four additional years to study the effects at a later time 
and with greater precision. The IR of lymphoma observed 
in the untreated population of this study, 16.6 per 100,000 
person-years, is comparable to the IR of lymphoma per 
100,000 person-years in the THIN database (1720) and in the 
UK general population (17 in females and 19 in males21).
Results are consistent with the findings of some obser-
vational studies5,6 but not others.7 The only published study 
conducted in children was restricted to users of pimecrolimus 
and reported a 2.6-fold increase in the standardized incidence 
ratio for lymphoma.22 In a cohort study of patients diagnosed 
with atopic dermatitis, T-cell lymphoma, primarily CTCL, 
was the only type of cancer associated with an increased 
risk in users of tacrolimus and pimecrolimus compared 
with untreated patients.5 In another cohort study, the IR of 
cutaneous forms of lymphoma was higher in new users of 
tacrolimus and pimecrolimus than in untreated subjects.6 
However, in that study, there was an increased risk for the 
use of high-potency TCSs versus medium-potency TCSs, 
suggesting reverse causation, with early manifestations of 
undiagnosed cutaneous lymphoma triggering the initiation 
of treatment, and an increased surveillance of patients with 
more severe forms of cutaneous diseases. Other studies have 
not detected any association between lymphoma and the use 
of topical calcineurin inhibitors7 or between nonmelanoma 
skin cancer and the use of pimecrolimus.8
An increased risk of cancer among solid organ trans-
plant recipients has been well documented, particularly for 
infection-related skin malignancies.23–26 The risk of lym-
phoma in patients undergoing organ transplantation is closely 
related to the intensity of immunosuppression (ie, number 
and dose of immunosuppressive agents used) and ensuing 
inability of the immune system to control Epstein–Barr 
virus infection.27 Concerns about a potential increase in the 
risk of cancer from the use of topical tacrolimus emerged 
from the increased risk observed in animal studies, organ 
transplant patients treated with systemic tacrolimus, and a 
small number of case reports.27–29 Prolonged administration 
of systemic tacrolimus at sustained high concentrations in 
transplant patients,  alongside other immunosuppressant 
drugs such as corticosteroids, has been associated with an 
increased rate of lymphomas, nonmelanoma skin cancer, 
and melanomas in sun-exposed areas.27–33 The hypothetical 
mechanisms through which topical immunosuppressants such 
as calcineurin inhibitors could increase the risk of cancer 
in patients with atopic dermatitis involve the development 
of local immunosuppression at the application site and/or 
systemic immunosuppression due to systemic absorption. 
Large, severe skin lesions could increase the cutaneous 
absorption of these topical medications, leading to higher 
systemic concentrations that may cause immunosuppression, 
particularly in children.
The increased risk of lymphoma found in our study could 
be compatible with a causal effect of exposure to tacrolimus 
and pimecrolimus. However, several limitations should be 
considered. Atopic dermatitis and severity of atopic dermati-
tis have in themselves been associated with an increased risk 
of lymphoma.9 This relation could introduce confounding by 
indication as patients with more severe atopic dermatitis are 
more likely to be treated with tacrolimus or pimecrolimus 
than with TCSs. This confounding could be more relevant for 
tacrolimus than for pimecrolimus as tacrolimus is indicated 
for more severe atopic dermatitis. In our study, we under-
estimated the occurrence of atopic dermatitis, as available 
information was mainly based on hospital discharge diagno-
ses. Also, we ascertained atopic dermatitis severity indirectly 
through the intensity of use of health care resources and type 
of prescriber of the first prescription. Although we corrected 
IRRs for the effect of type of prescriber using probabilistic 
bias analysis, residual confounding can still be present. The 
dose–response relationship observed with cumulative dose 
for CTCL could be compatible with a causal effect and also 
with residual confounding arising from the severity of atopic 
dermatitis. We should consider that the cutoff values for 
cumulative dose categories used in this study were relatively 
low (eg, tacrolimus high dose cutoff value was 0.10 g, which 
corresponds to 5.6 tubes of 60 g of tacrolimus 0.03% oint-
ment or 1.7 tubes of 60 g of tacrolimus 0.1% ointment). Also, 
data on the patterns of use of tacrolimus and pimecrolimus in 
the study populations show that the mean number of prescrip-
tions per patient was low in both children and adults (around 
two prescriptions in most databases).13 These data are more 
consistent with a severity bias than with a causal effect of 
tacrolimus and pimecrolimus. Severity of atopic dermatitis 
could also lead to increased monitoring and surveillance 
bias. The stronger associations found in the first 6 months of 
treatment are consistent with increased surveillance.
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Reverse causation could have introduced bias in our 
results. CTCL can be misdiagnosed as atopic dermatitis and 
treated as such long term, up to 10 years.34 This possibility 
is supported by the findings by Hui et al;5 in four of the 16 
patients with atopic dermatitis, those researchers found evi-
dence of suspected CTCL recorded in the medical records 
before the initiation of treatment. Reverse causation would 
result in the overestimation of the measures of effect. In our 
study, the analysis of time since first exposure showed that 
the IRR for CTCL associated with tacrolimus was maintained 
during follow-up, suggesting the possibility of long-term 
reverse causation. The increased IRR associated with lag 
times of 12 and 24 months, although compatible with a 
long induction period, could also support the hypothesis of 
reverse causation.
We required users of tacrolimus and pimecrolimus to be 
first-ever users of these medications. However, to prevent 
including in the comparator group patients with very early 
stages of atopic dermatitis, the cohorts of TCSs included 
new and prevalent users. Inclusion of prevalent users of 
TCSs could result in survival bias, through the depletion of 
patients with early events, and subsequent overestimation 
of the effect of tacrolimus and pimecrolimus. However, the 
potential bias is probably minimal as there was no strong 
evidence of increased risk of lymphoma and skin cancer 
associated with the use of TCSs.
Results from the comparison of TCS users with the 
untreated population could be explained by residual con-
founding, as the effect of risk factors such as diagnosis of 
atopic dermatitis and severity of atopic dermatitis were not 
taken into account.
Conclusion
We found increased rates of lymphoma in children initiating 
treatment with topical tacrolimus and of CTCL in adults 
initiating treatment with topical tacrolimus or pimecrolimus. 
These findings are compatible with a causal effect and also 
with residual confounding by severity of atopic dermatitis, 
increased monitoring of more severe patients, and reverse 
causation. The low absolute magnitude of risks for lymphoma 
and CTCL means that even if the increased risk observed is 
causal, the excess risk for an individual patient would be small.
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